Sinphar Pharmaceutical Co.,Ltd.

TWSE:1734 Stock Report

Market Cap: NT$5.6b

Sinphar PharmaceuticalLtd Past Earnings Performance

Past criteria checks 4/6

Sinphar PharmaceuticalLtd has been growing earnings at an average annual rate of 58.6%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 6% per year. Sinphar PharmaceuticalLtd's return on equity is 9.5%, and it has net margins of 10.9%.

Key information

58.6%

Earnings growth rate

58.6%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate6.0%
Return on equity9.5%
Net Margin10.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Impressive Earnings May Not Tell The Whole Story For Sinphar PharmaceuticalLtd (TWSE:1734)

Apr 02
Impressive Earnings May Not Tell The Whole Story For Sinphar PharmaceuticalLtd (TWSE:1734)

Would Sinphar PharmaceuticalLtd (TPE:1734) Be Better Off With Less Debt?

Feb 15
Would Sinphar PharmaceuticalLtd (TPE:1734) Be Better Off With Less Debt?

Can You Imagine How Sinphar PharmaceuticalLtd's (TPE:1734) Shareholders Feel About The 52% Share Price Increase?

Dec 22
Can You Imagine How Sinphar PharmaceuticalLtd's (TPE:1734) Shareholders Feel About The 52% Share Price Increase?

Revenue & Expenses Breakdown

How Sinphar PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TWSE:1734 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,04533375797
30 Jun 243,011361739116
31 Mar 242,969405723128
31 Dec 232,963375673133
30 Sep 232,977277668260
30 Jun 232,970269658254
31 Mar 232,959247635260
31 Dec 222,857225622272
30 Sep 222,735198599254
30 Jun 222,59397583440
31 Mar 222,48515571479
31 Dec 212,434-38560512
30 Sep 212,333-77538537
30 Jun 212,405-53537420
31 Mar 212,380-50536447
31 Dec 202,388-29535462
30 Sep 202,52060531494
30 Jun 202,45860522530
31 Mar 202,44726538547
31 Dec 192,39514560528
30 Sep 192,322-13578495
30 Jun 192,272-17586441
31 Mar 192,2296580390
31 Dec 182,2169568376
30 Sep 182,18623549352
30 Jun 182,19252541342
31 Mar 182,18662525346
31 Dec 172,13437510363
30 Sep 172,15956519370
30 Jun 172,15836525376
31 Mar 172,14024535386
31 Dec 162,13417549383
30 Sep 162,19042549368
30 Jun 162,15931559369
31 Mar 162,20824574346
31 Dec 152,18714571343
30 Sep 152,2392576381
30 Jun 152,236-4588365
31 Mar 152,44476587367
31 Dec 142,642163589350
30 Sep 142,654142600310
30 Jun 142,910253587286
31 Mar 142,772241573251
31 Dec 132,578301576226

Quality Earnings: 1734 has high quality earnings.

Growing Profit Margin: 1734's current net profit margins (10.9%) are higher than last year (9.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 1734 has become profitable over the past 5 years, growing earnings by 58.6% per year.

Accelerating Growth: 1734's earnings growth over the past year (20.3%) is below its 5-year average (58.6% per year).

Earnings vs Industry: 1734 earnings growth over the past year (20.3%) exceeded the Pharmaceuticals industry 17.2%.

Return on Equity

High ROE: 1734's Return on Equity (9.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y